Vésale Bioscience

by Bacteriophage.news
Bacteriophage.news Company Biotechnology Vesale Bioscience

Vésale Bioscience is a Belgian biotechnology company created in 2018 as a spin-out of Vésale Pharma specializing in treatments of the microbiome.

Vésale Bioscience fight antibacterial multi-resistant infections (AMR) with personalized phage therapy solutions:

  1. The company has developed a fast diagnostic tool Luminophage®, an automated Phagogram®, that will recommend in a couple of hours (instead of days/weeks) the optimal phages association to fight the specific patient’s bacteria.
  2. With the help of a phage library, the company can produce (GMP) and deliver the selected phages as API for tailored magistral preparations within 24-48 hours. This approach dramatically increases the success rate of AMR treatments and allows to treat acute and chronic infections at the hospital.

Vésale Bioscience has developed a broad scientific network, including the Queen Astrid Military Hospital (BE), Laboratory of Brussels University Hospitals (BE), Eliava Institute (Georgia), and benefits from grants of the Walloon Region to develop its innovative solutions for human and veterinary use.

Bacteriophage portfolio:

The Vésale Bioscience phage library consists of difficult-to-treat infections caused by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumonae, bacteria that are responsible for 70% of AMR infections in EU & US.

This website uses cookies. Accept Read More